Vobarilizumab
Monoclonal antibody | |
---|---|
Type | Single-chain variable fragment |
Source | Humanized |
Target | IL6R |
Clinical data | |
Other names | ALX0061 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C1118H1757N315O364S8 |
Molar mass | 25691.68 g·mol−1 |
Vobarilizumab (INN; development code ALX0061) is a humanized monoclonal antibody designed for the treatment of inflammatory autoimmune diseases.[1][2]
This drug was developed by Ablynx NV.
References[]
Categories:
- Drugs not assigned an ATC code
- Monoclonal antibody stubs
- Monoclonal antibodies